Magdalena Biosciences, Inc. has a paradigm shifting drug development approach, 12-24 months from plant collection to clinical POC study initiation possible; de-risk early with higher probability for future FDA-approved botanical drugs; efficacious due to history of medicinal use. MB2500, first IND, ready to file in 2025 for improvement in executive function in ADHD or cognitive deficit in schizophrenia. Statistically significant efficacy in animal models of disease (depression, anxiety and cognitive deficit); improvement in cognition equivalent or better than donepezil, the drug most commonly used to treat Alzheimer’s disease. PET scan data show increase in neuronal activity in the prefrontal cortex with statistically significant increases in connectivity among brain areas leading to potential neuronal remodeling relevant to various psychiatric disorders. Pipeline of drug candidates in ADHD, schizophrenia, anxiety, depression and cognition. Sustainable supply; benefit sharing; IP.